Artificial Intelligence
Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami
MIAMI, July 09, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company Ehave has hired an Institutional Review Board (IRB) as it prepares to launch ketamine clinical Trials in Miami with Tristar Wellness. The IRB will review all research involving human subjects and implement policies and procedures regarding such research. The primary function of the IRB is to protect the rights of human subjects. Review and approval by the IRB will help subjects and researchers assess research protocols by a peer group who can objectively identify potential risks and the accommodations made to minimize them. The IRB will be responsible for:
- The review and approval of applications to conduct research involving human subjects.
- Continuing review of approved protocols.
- Monitoring of reported adverse events involving subjects in approved protocols.
Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research. Ehave previously announced it is ahead of schedule and plans launch its KetaDASH www.ketadash.com ketamine IV therapy by the end of the second quarter. In addition to hiring the IRB, Ehave has engaged legal counsel to advise the Company on the rollout of KetaDASH and secured an umbrella policy to cover liability and malpractice insurance on each home delivery service. Within the next 60 days, KetaDASH plans to begin signing up customers and start referring to local clinics. Ehave is currently in negotiations with multiple entities to franchise the KetaDASH platform, or buy license across the United States.
Dane Jackman, Managing Director of Tristar Wellness, said, “This partnership marks the first in a line of Ketamine related micro-trials slated at Tristar Wellness, Miami Beach. We truly believe there is immense opportunity to explore the benefits of ketamine treatment beyond helping for the known ailments such as depression, anxiety, PTSD, etc. We’re gearing up to explore more research into Ketamine therapy and other neurological conditions such as Parkinson’s disease and addiction to name a few.”
The KetaDASH platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously. This gives the clinic an opportunity to increase revenues by treating patients who are unable to come to their office. KetaDASH will provide the platform for medical practitioners to administer Ketamine intravenously to patients at home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the amount of potentially addictive pain medication required after certain medical procedures. Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression.
Ehave Chief Executive Officer, Ben Kaplan, said, “Hiring an IRB is a very important step in our ketamine clinical Trials in Miami with Tristar Wellness. The safety of the individuals participating in our trials is of utmost importance to both Ehave and Tristar Wellness. This is a tremendous milestone for our shareholders, and we are pleased with the progress we have made.” Mr. Kaplan continued, “KetaDASH will give us the ability to provide ketamine as a psychedelic-assisted therapy for individuals suffering from depression, anxiety, PTSD or other mental or emotional health challenges. We look forward to building a revenue producing platform.”
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.
Contact: Ehave Inc.
Media Inquiries: Gabe Rodriguez
[email protected]
Investor Relations:
Email: [email protected]
Phone: (623) 261-9046
BIRMINGHAM, England, May 6, 2024 /PRNewswire/ — Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.
The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise, delivers light directly to the site of the injury.
Their latest research, published in Bioengineering and Translational Medicine, determined an optimal ‘dose’ for this novel approach, and showed it can deliver therapeutic improvements including significant restoration of sensation and movement, and regeneration of damaged nerve cells.
Researchers led by Professor Zubair Ahmed used cell models of SCI to determine the frequency and duration of light required to achieve maximum restoration of function and stimulate nerve cell regrowth.
They found delivery at a wavelength of 660nm for one minute a day increased cell viability (the number of live cells) by 45% over five days’ treatment.
Professor Ahmed said: “The effect of 660nm light was both neuroprotective, meaning it improved survival of nerve cells, and neuroregenerative, meaning it stimulated nerve cell growth.”
The researchers also investigated the effect of light therapy in preclinical models of SCI, using an implantable device and transcutaneous delivery with the light source placed against the skin. They showed comparable results for both methods, with a one-minute dose of 660nm light, delivered daily for seven days resulting in reduced tissue scarring, increased levels of proteins associated with nerve cell regeneration, improvements in the connections between cells and significant functional recovery.
This is the first time transcutaneous and direct light delivery have been compared in SCI. Professor Ahmed said: “To make light therapy viable for treating SCI in humans an implantable device will be required, to provide line of sight to damaged tissue and the opportunity for greater accuracy and standardise dosing without impedance due to the thickness of the skin and other tissues surrounding the spinal cord.”
The researchers are planning to develop an implantable device for use in humans with traumatic SCI. They have already received further funding and are seeking commercial partners or investors to develop a prototype device to take into first-in-man clinical trials.
Full release here.
University of Birmingham Enterprise helps researchers turn ideas into products and services that meet real-world needs. Follow us on LinkedIn and X.
Photo: https://mma.prnewswire.com/media/2404909/University_of_Birmingham_Enterprise.jpg
Media enquiries: Ruth Ashton
Commercial enquiries: Veemal Bhowruth
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/red-light-therapy-for-repairing-spinal-cord-injury-passes-milestone-302136233.html
Artificial Intelligence
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
LONDON, May 6, 2024 /PRNewswire/ — TerraPay, a leading global money movement company, is excited to announce the appointment of Hassan Chatila as Vice President – Global Head of Network.
This key addition to TerraPay’s global network leadership also marks a critical step in the company’s ongoing strategy to simplify and streamline global money movement for businesses and individuals alike, underscoring its commitment to enhancing its network capabilities.
With over 20 years of experience in the cross-border payments, Hassan brings with him a rich legacy of leadership and innovation. Before joining TerraPay, he served as the Global Head of Western Union’s Account Payout Network, where he played a pivotal role in expanding and optimizing the network to support seamless global transactions. His impressive career portfolio also includes key leadership roles at Earthport and Temenos, where he led significant payments transformation initiatives and drove substantial growth.
In this new role at TerraPay, Hassan will lead the expansion and optimization of TerraPay’s global payout network. He will work closely with internal and external stakeholders to enhance the network’s capabilities, ensuring that TerraPay continues to offer its partners transparent and efficient payment solutions.
Welcoming Hassan to the team, TerraPay Founder and CEO, Ambar Sur, said, “It gives me great pleasure to welcome Hassan on board. As an industry expert, he comes with a highly reputable cross-border payment expertise and deep leadership experience. On TerraPay’s journey of growth, Hassan’s appointment is a critical step in furthering our network expansion goals. I look forward to working together and further deepen TerraPay’s position as a global money movement leader.”
Hassan Chatila, VP – Global Head of Network, TerraPay, commented on his new role, saying, “I am thrilled to join TerraPay at this pivotal time. Over the years, TerraPay has built an expansive global money movement network driven by the mission to build a borderless world of payments. I look forward to leveraging my experience to further develop our network capabilities, create new opportunities across markets and help TerraPay achieve its ambitious goals.”
For media inquiries, please contact [email protected]
About TerraPay
TerraPay simplifies global money movement – by providing a single connection to the most expansive cross-border payments network regulated in 31 global markets and enabling payments to 144 receive countries, 210+ send countries, 7.5Bn+ bank accounts and 2.1Bn+ mobile wallets. TerraPay is on a mission to connect a borderless financial world, making moving money everywhere instant, reliable, transparent and fully compliant. TerraPay pushes the boundaries for global businesses – ranging from banks, fintechs and money-transfer operators to travel businesses, creator economy platforms and e-commerce marketplaces – while driving financial inclusion in even the most inaccessible markets. Founded in 2014, TerraPay is headquartered in London, with global offices in Bangalore, Dubai, Miami, Bogota, Dar es Salaam, Kampala, Hague, Dakar, Joburg, Nairobi, Milan, Singapore and is expanding rapidly, having received funding from leading investors, including the IFC (the World Bank), Prime Ventures, Partech Africa and Visa.
Logo: https://mma.prnewswire.com/media/1222771/TerraPay_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/terrapay-continues-to-attract-top-industry-talent-names-hassan-chatila-as-vice-president-and-global-head-of-network-302135445.html
PARIS, May 6, 2024 /PRNewswire/ — Stonal, the leading data management platform for real estate owners and investors in Europe, has announced a strategic investment by Aareon, Europe’s trusted provider of SaaS solutions for the property industry, to accelerate its European expansion.
Founded in 2017 by Michel Tolila, the current executive chairman, and Jean-Maurice Oudot, Stonal’s mission is to deliver data quality at scale for asset owners and investors. Its collaborative AI-powered platform extracts information from documents and blueprints, creating an accurate and up-to-date database on buildings open to stakeholders such as property managers, surveyors, and insurers. Its decision-making modules offer ESG reporting and CapEx planning to increase returns, improve productivity and preserve value.
Since its inception, the company has quickly expanded into residential and commercial real estate. In early 2024, Stonal launched its proprietary StonalGPT, the first generative artificial intelligence solution designed for real estate owners and investors, establishing itself as one of the pioneers in this field.
Robin Rivaton, CEO of Stonal: “The real estate industry, both residential and commercial, is at a crossroads. AI is a massive opportunity to reshape the sector in a remarkable way, but it still requires a significant amount of data on which to train these systems. Thanks to the strategic partnership with Aareon we will reach such a scale and accelerate our European expansion.”
Aareon is the trusted provider of SaaS solutions for the European property industry. With locations across France, Germany, the Netherlands, Spain, Sweden, and the United Kingdom, Aareon serves 13,000 customers totalling 18 million units.
Harry Thomsen, CEO of Aareon: “Investing in Stonal is a strategic step to strengthen our “Aareon Sustain” product portfolio and amplify our proficiency in AI technology across the Aareon Group. With an expected uptick in the need for robust data management solutions, this collaboration not only reinforces the existing partnership between Stonal and Aareon in France but also equips us to meet our customers’ needs and deliver unrivalled innovation and operational excellence.”
Aareon’s investment in Stonal reflects the growing appetite of the real estate sector for technological solutions that enable it to address the major challenges it faces, applying to both larger companies and smaller ones. Expanding ESG expectations, increased CapEx for greener properties, stringent building safety regulations, higher vacancy due to remote work for offices, all converge in the context of high interest rates. The capacity to evaluate risks and make well-informed decisions promptly is now more crucial than ever.
Stonal was advised on this deal by Lazard, Aareon by Vulcain.
About StonalFounded in 2017, Stonal is the leading data management platform for real estate owners and investors in Europe. It helps more than 130 clients, REITs, insurers, housing organisations, asset managers, family offices, to manage a combined portfolio of more than 200 million sqm (including 1.6 million housing units) across all Europe. With 150 employees, Stonal is present in France and the UK.
Contact: Perrine ABRARD, Stonal CMO [email protected]
About AareonAareon is Europe’s trusted provider of SaaS solutions for the property industry, leading the charge towards a digital future. Passionately committed to connecting people, process, and property, Aareon brings the ecosystem closer together. Our Property Management System, powered by smart software solutions, promotes efficient property management and maintenance, enabling superior digital experiences for everyone involved. In our continuous pursuit of innovation, Aareon remains the industry’s reliable partner, inspiring positive change for sustainable spaces for all.
With a dedicated team of around 2,000 professionals, Aareon achieved pro forma revenues of €410 million and a pro forma Adjusted EBITDA of €137 million in 2023.
Logo: https://mma.prnewswire.com/media/2404363/Stonal_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/aareon-invests-up-to-100m-in-ai-powered-proptech-stonal-302135639.html
-
Artificial Intelligence3 days agoCleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized6 days agoIntel unveils AI-Platform Innovation for Paris 2024
-
Artificial Intelligence6 days agoSUNRATE partners with YeePay to empower Chinese companies to navigate global expansion
-
Uncategorized3 days ago
Improving the Developer Journey in Crafting Artificial Intelligence Applications
-
Artificial Intelligence5 days agoAppdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized3 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence3 days agoBitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence3 days ago5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
